Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study

PURPOSE: Preclinical studies suggest PARP inhibition (PARPi) induces immunostimulatory micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade. We conducted a phase 2 trial of PARPi olaparib and anti-PD-L1 durvalumab and collected paired fresh core biopsies and blood...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Lampert, Erika J., Zimmer, Alexandra, Padget, Michelle, Cimino-Mathews, Ashley, Nair, Jayakumar, Liu, Yingmiao, Swisher, Elizabeth M., Hodge, James W., Nixon, Andrew B., Nichols, Erin, Bagheri, Mohammad H., Levy, Elliott, Radke, Marc R., Lipkowitz, Stanley, Annunziata, Christina M., Taube, Janis M., Steinberg, Seth M., Lee, Jung-Min
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7442720/
https://ncbi.nlm.nih.gov/pubmed/32398324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0056
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller